Korean J Med.  2014 Jun;86(6):655-663.

Helicobacter pylori-related Peptic Ulcer Disease

• Seo SI
• Kim HY

Abstract

Although the worldwide prevalence of Helicobacter pylori (H. pylori) infection has decreased, peptic ulcer disease (PUD) remains prevalent due to increased usage of non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin. In recent years, the prevalence of H. pylori infection in PUD cases and the distribution of PUD have changed in Korea. The incidence of idiopathic H. pylori-negative ulcers has increased, and research is needed to determine the cause of these idiopathic ulcers. The eradication of H. pylori infection decreases PUD recurrence, and plays a crucial role in the treatment of PUD. The H. pylori test-and-treat strategy is beneficial for patients starting NSAIDs and long-term aspirin users with a history of bleeding ulcers. Although the H. pylori eradication rate is declining steadily due to antibiotic resistance, especially to clarithromycin, current guidelines still recommend standard triple therapy, including a proton pump inhibitor, amoxicillin, and clarithromycin, as a first-line therapy. Recently, various treatment regimens, including sequential or concomitant therapies, have been developed in an attempt to overcome the low eradication rate observed with standard triple therapy. The aim of this article is to review recent trends in H. pylori-related PUD, focusing on epidemiology and treatment strategies.

Keyword

Helicobacter pylori peptic ulcer; Epidemiology; Treatment

MeSH Terms

Amoxicillin
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Clarithromycin
Drug Resistance, Microbial
Epidemiology
Helicobacter pylori
Helicobacter*
Hemorrhage
Humans
Incidence
Korea
Peptic Ulcer*
Prevalence
Proton Pumps
Recurrence
Ulcer
Amoxicillin
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Clarithromycin
Proton Pumps